The Old and the New in the Treatment of Type 2 Diabetes: Focus on the Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Metformin
|
|
- Eileen Wilkinson
- 6 years ago
- Views:
Transcription
1 Clinical Medicine Insights: Therapeutics C o n s i s e R e v i e w Open Access Full open access to this and thousands of other papers at The Old and the New in the Treatment of Type 2 Diabetes: Focus on the Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Metformin Giovanni Anfossi, Isabella Russo, Katia Bonomo and Mariella Trovati Internal Medicine III University Unit, San Luigi Gonzaga Faculty of Medicine and Department of Clinical and Biological Sciences of the Turin University, San Luigi Gonzaga Hospital, Orbassano (Turin) Italy. giovanni.anfossi@unito.it Abstract: Type 2 diabetes mellitus (T2DM) is a complex multifactorial disease which affects the length and quality of life by severe chronic complications. Chronic hyperglycemia, which is the main alteration in T2DM, is strictly related to microvascular complications (such as retinopathy and nephropathy) and neuropathy, whereas large vessel atherosclerosis is also dependent on lipid and hemostasis abnormalities, arterial hypertension and other known cardiovascular risk factors. An early intervention to control hyperglycemia and to prevent deterioration of β-cell function is considered mandatory in patients with T2DM to minimize the risk of chronic complications. Recently, the availability of new pharmacological agents with different targets, including the activation of the incretin system has allowed the proposal of more effective strategies for early treatment of metabolic alterations in patients with T2DM. This commentary will focus on the role of new oral agents influencing the incretin system and the putative advantages of their co-administration with metformin, an old, effective anti-hyperglycemic agent also able to exert beneficial actions on arterial vessels, reducing the risk of macrovascular-related events. The vasoprotective role of metformin is largely independent of its hypoglycemic action, and has been ascribed to pleiotropic effects. Keywords: dipeptidyl peptidase-4, metformin, sitagliptin, type 2 diabetes mellitus, vildagliptin Clinical Medicine Insights: Therapeutics 2010: This article is available from the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. The authors grant exclusive rights to all commercial reproduction and distribution to Libertas Academica. Commercial reproduction and distribution rights are reserved by Libertas Academica. No unauthorised commercial use permitted without express consent of Libertas Academica. Contact tom.hill@la-press.com for further information. Clinical Medicine Insights: Therapeutics 2010:2 255
2 Anfossi et al Commentary Strategy and Selection Criteria Searches for original articles and review from 1985 to August 2009 focusing on metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors were performed in MEDLINE and PubMed electronic databases. The search terms were: metformin, diabetes, insulin resistance, obesity, incretin glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP). All papers identified were English language, full text papers and were selected on the basis of relevance and novelty; a priority was given to those published in peer-reviewed journals, from the past 5 years without excluding older publications commonly referenced or highly regarded. Introduction The International Diabetes Federation estimated that in 2007 the number of patients affected by type 2 diabetes mellitus (T2DM) reached 240 million worldwide, i.e. more than 5% of the adult population. 1 This multifactorial and progressive disease, caused by a combination of insulin resistance and β-cell dysfunction with decreased insulin secretion, 2,3 is associated with long-term complications, mainly involving blood vessels and peripheral nerves, which affect the length and quality of life. 4 Clear evidence indicates that chronic hyperglycemia plays a major pathogenic role in the development of microvascular complications (such as retinopathy and nephropathy) and neuropathy 5 whereas large vessel atherosclerosis, which is responsible of coronary, cerebral and lower limb atherothrombotic damage, also depends on lipid and hemostasis abnormalities, arterial hypertension and other known cardiovascular risk factors. 6 In patients with T2DM early interventions to control hyperglycemia and to prevent deterioration of β-cell function are considered pivotal to minimize the overall risk of developing chronic complications. 7 A therapeutic approach to achieve this target includes intervention regarding life-style and the use of metformin as a first-line pharmacological strategy; 8 however, this approach and the combination with sulphonylureas in non responsive patients seldom achieve and maintain optimal glycemic control. 9,10 Recently, however, this scenario has changed due to the availability of newer families of pharmacological agents (either injectable or oral) with different molecular targets and specific indication to control hyperglycemia and progression of β-cell dysfunction, as extensively reviewed by Corsino and Coll. 11 The Incretin System and its Role in Glycemic Control The endogenous incretin system, which accounts for an increased insulin release after an oral glucose load in comparison with intravenous administration, 12 is represented by the neuroendocrine hormones glucagon like peptide-1 (GLP-1) and glucose dependent insulinotropic hormone (GIP), small peptides of 30 and 42 amino acids, respectively, which are released from the L and K cells of the gastrointestinal tract, as a response to intraluminal glucose. 13,14 Both hormones cause a glucose dependent increase in insulin secretion; GLP-1 influences also insulin biosynthesis under hyperglycemic conditions, inhibits glucagon release, 14,15 and is associated with increased satiety, possibly because it reduces the rate of gastric emptying. 14 Indirect benefits on the cardiovascular system are recognized to incretins depending on weight reduction over time, improvements in arterial blood pressure and circulating lipid pattern, and reduction of inflammatory markers and insulin resistance. 16,17 The incretin effects on insulin secretion, however, are blunted by degradation through the ubiquitous serine protease dipeptidyl peptidase-4 (DPP-4). 14 Type 2 diabetic patients have reduced circulating levels of GLP-1 but retain the ability to respond to this hormone: therefore, it is possible to improve glycemic control through administration of exogenous GLP-1 analogs (exenatide, liraglutide) 18 or molecules that prolong the activity of endogenous GLP-1 and GIP by circumventing or reducing the rate of degradation by DPP DPP-4 inhibitors DPP-4 inhibitors are small molecules absorbed from the gastrointestinal tract, which decrease the activity of the enzyme over 80% They enhance meal-related circulating levels of incretins close to the physiological range, increasing their effects on glucose dependent stimulation of insulin secretion and suppression of glucagon output. 18 The effects on gastric emptying retardation and appetite reduction and weight loss are still controversial Clinical Medicine Insights: Therapeutics 2010:2
3 Old and new treatments for type 2 diabetes As extensively reviewed by Corsino and Coll, two DPP-4 inhibitors, i.e. sitagliptin and vildagliptin, are available and investigated in clinical trials, and several others (saxagliptin, alogliptin, and denagliptin) are under evaluation. 11 Sitagliptin, the first orally bioavailable selective DPP-4 inhibitor approved by the Federal Drug Administration (FDA), exhibits rapid absorption and elevated selectivity for DPP-4 in comparison with other DPP enzymes; 18,19 through this mechanism both acute and chronic studies showed that it preserves the circulating levels of intact GIP and GLP-1 following meals and reduces blood glucose levels without significant increases in hypoglycemic events. 18,19 Clinical phase III trials demonstrated a reduction of glycated hemoglobin A 1c (HbA 1c ) levels ranging 0.79% to 0.94%, in relationship to the employed doses. 19 Sitagliptin is moderately bound to plasma proteins and does not exhibit clinically relevant interactions with drugs that use the cytochrome P450 system or p glycoprotein transport system. Vildagliptin is the second DPP-4 inhibitor approved in Europe; similar to sitagliptin, it is rapidly absorbed by the gastro-enteric tract with maximal plasma concentrations within 1 2 hours; 20 its pharmacokinetic properties support a once daily dosing regimen. 20 The drug interactions of vildagliptin are limited: in particular, in clinical trials significant interactions with pioglitazone, metformin, or glibenclamide have been excluded. The pharmacology of metformin The glucose lowering effect of guanidine derivatives, i.e. phenformin, buformin and metformin, was observed starting from the 1950s. Phenformin and buformin were withdrawn from the pharmacopoeia in the early 1970s owing to their ability to induce lactic acidosis and their association with an increased cardiac mortality. Metformin (N,N-dimethyl biguanide), a less lipophilic biguanide, was proved safer and, after about 20 years of use in Europe, was approved for use in the USA in After single dose oral administration, metformin is absorbed in the upper intestinal tract within 6 hours with an absolute bioavailability ranging from 40% to 60%. 22 Co-administration with food slightly decreases and delays metformin absorption. 22 Metformin has a negligible binding to plasma proteins, 22 accumulates in the gastrointestinal tract, salivary glands and kidney, 22 does not undergo hepatic metabolism, 22 and, due to its elevated hydrophilia, is almost totally excreted, unchanged in the urine by glomerular filtration and tubular secretion. 22 Renal clearance of metformin is approximately 3.5 times greater than creatinine clearance and plasma half life is approximately 6.2 hours. 22 Both intestinal absorption and renal excretion of metformin are dependent on at least 2 organic cation transporters (OCT), namely OCT1 and OCT2; OCT1 mediated transport is the major mechanism for metformin to entry into hepatocytes and enterocytes, whereas OCT2 is the major renal metformin transporter. 23 As extensively reviewed, metformin exerts little effects on blood glucose concentrations in normoglycemic subjects; 22,24 its glucose-lowering action in T2DM is dependent on increased insulin sensitivity in liver and skeletal muscle in the presence of circulating insulin and of adequate β-cell function; 22,24,25 in particular, metformin reduces hepatic glucose output, 25 increases insulin stimulated glucose uptake by skeletal muscle and adipocytes, 22,24,25 and decreases the rate of intestinal glucose absorption. 26 Other extrahepatic actions of metformin include increased glucose transport and utilization by skeletal muscle due to the improvement in non oxidative glucose metabolism, 22,24 and an influence on the incretin system either through increased secretion of GLP-1, or inhibition of DPP-4 activity. 27 The United Kingdom Prospective Diabetes Study (UKPDS) firstly showed that in obese type 2 diabetic patients metformin improved macrovascular outcomes, including all cause death, and myocardial infarction in a subgroup of obese patients with newly diagnosed T2DM 28 more than sulphonylureas or insulin. 28 This observation identified metformin as the first line treatment of T2DM for reducing the risk of macrovascular events and induced investigations into the mechanisms involved in its vascular protective effects beyond its glucose lowering action. The vasoprotective role of metformin is largely independent of its hypoglycemic action and has been ascribed to pleiotropic effects. As recently reviewed, metformin has shown to exert beneficial actions on some mechanisms involved in atherothrombosis, including a reduction in insulin Clinical Medicine Insights: Therapeutics 2010:2 257
4 Anfossi et al resistance, an improvement in circulating lipid patterns, a reduction of a pro inflammatory status, a correction of pro thrombotic tendencies and an overall positive influence on vascular reactivity Experimental and clinical evidences indicate a decrease of advanced glycation end product (AGEs) formation and of oxidative stress as potential actions of the vascular effects of metformin, with improvement of endothelial function both in the macro and micro vasculature. 29,30 Combination Therapy with Metformin and Dipeptidyl Peptidase Inhibitors Rationale In the natural history of T2DM, the development of impaired glucose tolerance and finally of hyperglycemia occurs gradually over many years. Pancreatic β-cells, which are initially able to respond to increased insulin resistance by increasing insulin secretion to maintain normoglycemia, progressively reduce their function. 2,3 Metformin, which exerts neutral or protective effect on β-cell function, is recommended by guidelines as the first-line therapy in T2DM, 8 but presents a high rate of failure after relatively few years. Therefore, an intensification of the therapy by combination of agents with complementary mechanisms of action and lacking of pharmacological interferences is an almost mandatory step in the treatment of T2DM patients. As evidenced in Figure 1, the hypoglycemic effects of metformin and incretins are expected as additive, the actions on β-cell function as beneficial (differently from combination between sulphonylureas and metformin), the risk of hypoglycemic events as reduced and the effect of body weight as neutral. An additional aspect of this combination therapy derives from the evidence that metformin per se increases plasma levels of GLP Finally, recent evidence indicates some incretin mediated beneficial effects on vasculature, which could be additive to those of metformin (Table 1). Food Metformin Insulin resistance GLP-1 GIP Blood glucose DPP-4 DPP-4 inhibitors (Sitagliptin, Vildagliptin, Saxagliptin, Alogliptin, Denagliptin) Figure 1. Mechanisms involved in the hypoglycaemic effects of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors. Abbreviations: GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotopic hormone. 258 Clinical Medicine Insights: Therapeutics 2010:2
5 Old and new treatments for type 2 diabetes Table 1. Vasoprotective mechanisms ricognized to incretins and metformin. Incretins 1 reduce body weight improve plasma lipid pattern ( HDL-cholesterol, triglycerides) decrease arterial blood pressure improve endothelial function decrease inflammation Metformin 2 reduces body weight improves plasma lipid pattern ( free fatty acids, VLDL- triglycerides, LDL-cholesterol) improves endothelial dysfunction improves pro-thrombotic state improve endothelial function decrease inflammation 1 Mudaliar et al. Eur J Intern Med. 2009;20 Suppl 2:S Bailey CJ. Cardiovasc Drugs Ther. 2008;22:215. Clinical studies Results of trials on glycemic control in T2DM patients utilizing the combination between metformin and DPP-4 inhibitors are available as recently reviewed for vildagliptin 32 and sitagliptin. 33 The evidence firstly indicated that the addition of a drug active on the incretin system improves the deterioration of glycemic control in patients treated with metformin as monotherapy. 32,33 Furthermore, additive effects on HbA 1c levels were shown with combination therapy in comparison with either drug alone. 32,33 Conclusion Current American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) treatment guidelines recommend metformin as the first line drug in the treatment of T2DM as monotherapy, 8 and indicate its combination with other anti hyperglycemic or with hypoglycemic agents, including sulphonylureas, glitazones, and insulin, as further therapeutic options in patients who fail to reach therapeutic targets. 8 The combination between metformin and DPP-4 inhibitors has to be considered as an effective therapeutic choice for patients with T2DM not adequately controlled by monotherapy due to the complementary and possibly additive effect on metabolic control and, probably, on vascular risk. Disclosures The authors report no conflict of interest in this work. Acknowledgements This study was partially supported by a grant from Italian Ministero dell Istruzione, Università e Ricerca (MIUR) within the project; The molecular basis of insulin resistance and their importance in the pathogenesis of the alterations of the vessel wall. (Local Coordinator: Giovanni Anfossi, National Coordinator: Amalia Bosia) and by 2 grants from Regione Piemonte (years 2004 and 2006). References 1. International Diabetes Federation. Diabetes Atlas. 3rd ed. Brussels, Belgium: International Diabetes Federation; Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6): Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Betacell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1): Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14): Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009;53(5 Suppl):S Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19): Gallwitz B. The fate of beta-cells in type 2 diabetes and the possible role of pharmacological interventions. Rev Diabet Stud. 2006;3(4): Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8): Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27(7): Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1): Clinical Medicine Insights: Therapeutics 2010:2 259
6 Anfossi et al 11. Corsino L, Cox ME, Rowell J, Green JB. Present and prospective pharmacotherapy for the management of patients with type 2 diabetes. Clinical Medicine: Therapeutics. 2009;1: Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24(10): Efendic S, Portwood N. Overview of incretin hormones. Horm Metab Res. 2004;36(11 12): Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-iv inhibitors in type 2 diabetes. Lancet. 2006;368(9548): Gonzalez C, Beruto V, Keller G, Santoro S, Di Girolamo G. Investigational treatments for type 2 diabetes mellitus: exenatide and liraglutide. Expert Opin Invest Drugs. 2006;15(8): Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation. 2008;117(4): Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Eur J Intern Med. 2009;20(Suppl 2):S Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548): Aschner P, Kipnes M, Lunceford M, Sanchez M, Mickel C, Williams- Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12): D Alessio A, Denney AM, Hermiller LM, et al. Treatment with the Dipeptidyl Peptidase-4 inhibitor Vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes J Clin Endocrinol Metab. 2009;94(1): Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9): Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5): Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics. 2008;9(4): Cusi K, Defronzo RA. Metformin: a review of its metabolic effects. Diabetes Reviews. 1998;6(1): Bailey CJ. Metformin an update. Gen Pharmacol. 1993;24(6): Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia. 2008; 51(8): Lindsay JR, Duffy NA, McKillop AM, et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med. 2005;22(5): UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131): Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther. 2008;22(3): Wiernsperger NF. 50 years later: is metformin a vascular drug with antidiabetic properties? Br J Diabetes Vasc Dis. 2007;7(5): Anfossi G, Russo I, Bonomo K, Trovati M. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol Jan 1, In press. 32. Halimi S, Schweizer A, Minic B, Foley J, Dejager S. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag. 2008;4(3): Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag. 2008; 4(4): Publish with Libertas Academica and every scientist working in your field can read your article I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely. The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I ve never had such complete communication with a journal. LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought. Your paper will be: Available to your entire community free of charge Fairly and quickly peer reviewed Yours! You retain copyright Clinical Medicine Insights: Therapeutics 2010:2
The Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationClinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE Clinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes PhD Thesis Abstract Key words:
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationDOI: /jemds/2014/2044 ORIGINAL ARTICLE
AN OBSERVATIONAL STUDY COMPARING SITAGLIPTIN TO METFORMIN AS A INITIAL MONOTHERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS Mohd. Riyaz 1, Imran 2, Rinu Manuel 3, Nidhisha K. Joseph 4 HOW TO CITE THIS ARTICLE:
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationData from an epidemiologic analysis of
CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated
More informationVolume : 05 Issue : 03 July-Sept Pages:
Middle East Journal of Applied Sciences Volume : 05 Issue : 03 July-Sept. 2015 Pages: 695-699 Efficacy and Safety of Vildagliptin as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Poorly Controlled
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationNew Treatment Options for Type 2 Diabetes: Incretin-Based Therapy
New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy is supported by an educational grant from Novo Nordisk Inc. This program
More informationIncretins: based therapy for type -2 Diabetes mellitus (T2DM)
Int. J. Pharm. Med. Res. 2014; 2(2):38-42 ISSN: 2347-7008 Review article International Journal of Pharmaceutical and Medicinal Research Incretins: based therapy for type -2 Diabetes mellitus (T2DM) Sinha
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationAbstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah
Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationComparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes
Draft Comparative Effectiveness Review Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationPathogenesis of Type 2 Diabetes
9/23/215 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? Pathogenesis
More informationDiabetes Care Publish Ahead of Print, published online September 22, 2008
Diabetes Care Publish Ahead of Print, published online September 22, 2008 Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes Mellitus and Inadequate
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationTherapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationCombination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
REVIEW Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential Nasser Mikhail Endocrinology Division, Olive View-UCLA Medical
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationMy Journey in Endocrinology. Samuel Cataland M.D
My Journey in Endocrinology Samuel Cataland M.D. 1968-2015 Drs Berson M.D. Yalow phd Insulin Radioimmunoassay Nobel Prize Physiology or Medicine 1977 Rosalyn Yalow: Radioimmunoassay Technology Andrew Schally
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationInitial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin
The journal of interventions in clinical practice www.drugsincontext.com CLINICAL COMMENTARY FULL TEXT ARTICLE Initial combination therapy for patients with type 2 diabetes mellitus: considerations for
More informationDiabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
More informationDiabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
More informationNovel anti-diabetic therapies
Prof. Manfredi Rizzo, MD, PhD ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of Palermo, Italy & ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of South
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationCurrent Status of Incretin Based Therapies in Type 2 Diabetes
Current Status of Incretin Based Therapies in Type 2 Diabetes DR.M.Mukhyaprana Prabhu Professor of Internal Medicine Kasturba Medical College, Manipal, Manipal University, India 2 nd International Endocrine
More informationTypes of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely
The Open Diabetes Journal, 2011, 4, 1-5 1 Open Access Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely Hidekatsu Yanai * and Hiroki Adachi Department of Internal
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More information(Incretin) ( glucagon-like peptide-1 GLP-1 ) GLP-1. GLP-1 ( dipeptidyl peptidase IV DPP IV ) GLP-1 DPP IV GLP-1 exenatide liraglutide FDA 2 2 2
007 18 189-194 (Incretin) Incretin ( ) -1 ( glucagon-like peptide-1 ) ( dipeptidyl peptidase IV ) liraglutide FDA ( Type diabetes mellitus ) -1 ( Glucagon-like peptide-1, ) ( Incretin ) ( Dipeptidyl peptidase
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationTreating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric
Treating Type 2 Diabetes with Bariatric Surgery Number (in Millions) of Persons with Diagnosed Diabetes, United States, 198 25 The number of Americans with diabetes increased from 5.6 to 15.8 million Guilherme
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationla prise en charge du diabète de
N21 XIII Congrès National de Diabétologie, 29 mai 2011, Alger Intérêt et place des Anti DPP4 dans la prise en charge du diabète de type 2 Nicolas PAQUOT, MD, PhD CHU Sart-Tilman, Université de Liège Belgique
More informationCombination treatment for T2DM
Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationNeuroprotective properties of GLP-1 - a brief overview. Michael Gejl Jensen, MD Dept. Of Pharmacology, AU
Neuroprotective properties of GLP-1 - a brief overview Michael Gejl Jensen, MD Dept. Of Pharmacology, AU mg@farm.au.dk Agenda Glucagon-like peptide (GLP-1) GLP-1 and neuronal activity GLP-1 in disease-specific
More information22 Emerging Therapies for
22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.
More informationUnderstanding the Mechanisms to Maintain Glucose
n posttest n Understanding the Mechanisms to Maintain Glucose Homeostasis: A Review for Managed Care Instructions After reading Understanding the Mechanisms to Maintain Glucose Homeostasis: A Review for
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationPROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT
CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationVICTOSA and Renal impairment DR.R.S.SAJAD
VICTOSA and Renal impairment DR.R.S.SAJAD February 2019 Main effect of GLP-1 is : Stimulating glucose dependent insulin release from the pancreatic islets. Slow gastric emptying Inhibit inappropriate
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationROLE OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN GLYCEMIC CONTROL AND CARDIOVASCULAR MORTALITY AND MORBIDITY
ROLE OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN GLYCEMIC CONTROL AND CARDIOVASCULAR MORTALITY AND MORBIDITY An Article Review By Dr.Shaikh Khalid Anwar, India (PG Diploma in Diabetes, MMSc in Diabetology Student
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationGLYXAMBI (empagliflozin-linagliptin) oral tablet
GLYXAMBI (empagliflozin-linagliptin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationDPP-4 Inhibitors: Strategies for PPG Control
Issue 2 Clinical Use o f In c r e t i n-based Therapies to Tr e at Type 2 Diabetes Term of Approval Release date: August 2009 Expiration date: August 31, 2010 DPP-4 Inhibitors: Strategies for PPG Control
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationInt. J. Pharm. Sci. Rev. Res., 22(2), Sep Oct 2013; nᵒ 21,
Research Article A Comparative Study to Evaluate the Efficacy and Safety of Vildagliptin as an Add-on Therapy to a Low-Dose Metformin vs an Uptitration of Metformin in Type 2 DM Patients Basavaraj Bhandare*
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More information